NCT02837991
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Registry record
- Lead sponsor
- Celldex Therapeutics
- Conditions
- Renal Cell Carcinoma (RCC); Clear-cell Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Kidney Neoplasms; Metastatic Renal Cell Carcinoma
- Primary completion
- Nov 16, 2018Actual
- Completion
- Locked
- Start
- Locked
- Enrollment
- Locked
- Interventions
- Locked
- Study type
- Locked
- Results on the registry
- Locked
- Record last updated
- Locked
Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerRecorded changes
0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.
Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.